Viewing Study NCT03240159


Ignite Creation Date: 2025-12-24 @ 3:01 PM
Ignite Modification Date: 2026-01-05 @ 5:15 PM
Study NCT ID: NCT03240159
Status: UNKNOWN
Last Update Posted: 2020-10-08
First Post: 2017-08-02
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Long Antagonist Protocol for IVF With Single Luteal Dose of Degarelix
Sponsor: Assisting Nature
Organization:

Study Overview

Official Title: Long Antagonist Protocol for IVF: a Proof of Concept for a Single Luteal GnRH- Antagonist Protocol
Status: UNKNOWN
Status Verified Date: 2020-10
Last Known Status: RECRUITING
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: A prospective study of three different doses of Degarelix in late luteal phase of women undergoing ovarian stimulation for IVF
Detailed Description: A prospective study of three different doses of Degarelix in late luteal phase of women undergoing ovarian stimulation for IVF:Single dose of Degarelix 24mg, 16mg and 12 mg, on day 24th of previous luteal face cycle. On day 2 of the cycle: will be measured: LH levels, estradiol levels, and FSH levels.

ON day 1 of the stimulation (depending day of the cycle): will be measured: LH levels, estradiol levels, and FSH levels.

On day 6 of the stimulation( depending day of the cycle):will be measured: LH levels, estradiol levels, and FSH levels.

On day 8 of the stimulation( depending day of the cycle):will be measured: LH levels, estradiol levels, and FSH levels.

On day 10 of the stimulation( depending day of the cycle):will be measured: LH levels, estradiol levels, and FSH levels.

Study Oversight

Has Oversight DMC: True
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: